Literature DB >> 25076114

Leukemogenesis in heterozygous PU.1 knockout mice.

Paula C Genik1, Irina Vyazunova, Leta S Steffen, Jeffery W Bacher, Helle Bielefeldt-Ohmann, Scott McKercher, Robert L Ullrich, Christina M Fallgren, Michael M Weil, F Andrew Ray.   

Abstract

Most murine radiation-induced acute myeloid leukemias involve biallelic inactivation of the PU.1 gene, with one allele being lost through a radiation-induced chromosomal deletion and the other allele affected by a recurrent point mutation in codon 235 that is likely to be spontaneous. The short latencies of acute myeloid leukemias occurring in nonirradiated mice engineered with PU.1 conditional knockout or knockdown alleles suggest that once both copies of PU.1 have been lost any other steps involved in leukemogenesis occur rapidly. Yet, spontaneous acute myeloid leukemias have not been reported in mice heterozygous for a PU.1 knockout allele, an observation that conflicts with the understanding that the PU.1 codon 235 mutation is spontaneous. Here we describe experiments that show that the lack of spontaneous leukemia in PU.1 heterozygous knockout mice is not due to insufficient monitoring times or mouse numbers or the genetic background of the knockout mice. The results reveal that spontaneous leukemias that develop in mice of the mixed 129S2/SvPas and C57BL/6 background of knockout mice arise by a pathway that does not involve biallelic PU.1 mutation. In addition, the latency of radiation-induced leukemia in PU.1 heterozygous mice on a genetic background susceptible to radiation-induced leukemia indicates that the codon 235 mutation is not a rate-limiting step in radiation leukemogenesis driven by PU.1 loss.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25076114     DOI: 10.1667/RR13738.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  5 in total

Review 1.  Evaluating biomarkers to model cancer risk post cosmic ray exposure.

Authors:  Deepa M Sridharan; Aroumougame Asaithamby; Steve R Blattnig; Sylvain V Costes; Paul W Doetsch; William S Dynan; Philip Hahnfeldt; Lynn Hlatky; Yared Kidane; Amy Kronenberg; Mamta D Naidu; Leif E Peterson; Ianik Plante; Artem L Ponomarev; Janapriya Saha; Antoine M Snijders; Kalayarasan Srinivasan; Jonathan Tang; Erica Werner; Janice M Pluth
Journal:  Life Sci Space Res (Amst)       Date:  2016-05-21

2.  Transcriptomic and proteomic analysis of mouse radiation-induced acute myeloid leukaemia (AML).

Authors:  Christophe Badie; Agnieszka Blachowicz; Zarko Barjaktarovic; Rosemary Finnon; Arlette Michaux; Hakan Sarioglu; Natalie Brown; Grainne Manning; M Abderrafi Benotmane; Soile Tapio; Joanna Polanska; Simon D Bouffler
Journal:  Oncotarget       Date:  2016-06-28

3.  Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia.

Authors:  Britta Will; Thomas O Vogler; Swathi Narayanagari; Boris Bartholdy; Tihomira I Todorova; Mariana da Silva Ferreira; Jiahao Chen; Yiting Yu; Jillian Mayer; Laura Barreyro; Luis Carvajal; Daniela Ben Neriah; Michael Roth; Johanna van Oers; Sonja Schaetzlein; Christine McMahon; Winfried Edelmann; Amit Verma; Ulrich Steidl
Journal:  Nat Med       Date:  2015-09-07       Impact factor: 53.440

Review 4.  PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML.

Authors:  Tom Verbiest; Simon Bouffler; Stephen L Nutt; Christophe Badie
Journal:  Carcinogenesis       Date:  2015-03-06       Impact factor: 4.944

5.  Tracking preleukemic cells in vivo to reveal the sequence of molecular events in radiation leukemogenesis.

Authors:  Tom Verbiest; Rosemary Finnon; Natalie Brown; Lourdes Cruz-Garcia; Paul Finnon; Grainne O'Brien; Eleanor Ross; Simon Bouffler; Cheryl L Scudamore; Christophe Badie
Journal:  Leukemia       Date:  2018-03-03       Impact factor: 11.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.